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Abstract: BACKGROUND Pathologic response to neoadjuvant chemotherapy (neoCTX) is a prognostic
factor in many cancer types, and early prediction would help to modify treatment. In patients with
gastric and esophagogastric junction (AEG) cancer, the accuracy of FDG PET-CT to predict early
pathologic response after neoadjuvant chemotherapy (neoCTX) is currently not known. METHODS
From a consecutive cohort of 72 patients, 44 patients with resectable, locally-advanced gastric cancer or
AEG Siewert type II and III received neoCTX after primary staging with endoscopic ultrasound, PET-
CT and laparoscopy. Overall, 14 patients did not show FDG uptake, and the remaining 30 were restaged
by PET-CT 14 days after the first cycle of neoCTX. Metabolic response was defined as decrease of tumor
standardized uptake value (SUV) by ￿35%. Major pathologic regression was defined as less than 10%
residual tumor cells. RESULTS Metabolic response after neoCTX was detected in 20/30 (66.7%), and
non-response in 10/30 (33.3%) patients. Among metabolic responders, n = 10 (50%) showed major and
n = 10 (50%) minor pathologic regression. In non-responders, n = 9 (90%) had minor and 1 (10%) a
major pathologic regression. This resulted in a sensitivity of 90.9%, specificity 47.3%, positive predictive
value 50%, negative predictive value 90% and accuracy of 63.3%. CONCLUSION Response PET-CT
after the first cycle of neoCTX does not accurately predict overall pathologic response. However, PET-
CT reliably detects non-responders, and identifies patients who should either immediately proceed to
resection or receive a modified multimodality therapy. TRIAL REGISTRATION The trial was registered
and approved by local ethics committee PB2016− 00769.
DOI: https://doi.org/10.1186/s12885-018-4477-4
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Abstract
Background: Pathologic response to neoadjuvant chemotherapy (neoCTX) is a prognostic factor in many cancer
types, and early prediction would help to modify treatment. In patients with gastric and esophagogastric junction
(AEG) cancer, the accuracy of FDG PET-CT to predict early pathologic response after neoadjuvant chemotherapy
(neoCTX) is currently not known.
Methods: From a consecutive cohort of 72 patients, 44 patients with resectable, locally-advanced gastric cancer or
AEG Siewert type II and III received neoCTX after primary staging with endoscopic ultrasound, PET-CT and
laparoscopy. Overall, 14 patients did not show FDG uptake, and the remaining 30 were restaged by PET-CT 14 days
after the first cycle of neoCTX. Metabolic response was defined as decrease of tumor standardized uptake value
(SUV) by ≥35%. Major pathologic regression was defined as less than 10% residual tumor cells.
Results: Metabolic response after neoCTX was detected in 20/30 (66.7%), and non-response in 10/30 (33.3%)
patients. Among metabolic responders, n = 10 (50%) showed major and n = 10 (50%) minor pathologic regression.
In non-responders, n = 9 (90%) had minor and 1 (10%) a major pathologic regression. This resulted in a sensitivity of
90.9%, specificity 47.3%, positive predictive value 50%, negative predictive value 90% and accuracy of 63.3%.
Conclusion: Response PET-CT after the first cycle of neoCTX does not accurately predict overall pathologic
response. However, PET-CT reliably detects non-responders, and identifies patients who should either immediately
proceed to resection or receive a modified multimodality therapy.
Trial registration: The trial was registered and approved by local ethics committee PB_2016–00769.
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Background
Cancer of the stomach (GC) and the distal esophagus
and esophagogastric junction (AEG) is a substantial glo-
bal health problem with around 1 million new cases and
750,000 deaths per year, accounting for estimated 10% of
all cancer-related deaths [1, 2]. In Europe and North
America, the overall 5-year survival for GC is approxi-
mately 25% [3], while superior outcomes with 5-year
survival rates of approximately 60% are reported in East
Asia [4].
The optimal medical treatment for advanced GC and
AEG is still a source of debate, but after the publication of
the randomized “MAGIC Trial” and “ACCORD Trial”,
neoadjuvant chemotherapy has become first choice for
the treatment of locally advanced GC and AEG, and
reported improved 5-year survival rates of 36 and 38%
respectively [5, 6]. This situation is similar for esophageal
and cardia cancers where the recently published ran-
domized “CROSS Trial”, using neoadjuvant chemora-
diation, reported 3-year survival rates of 59% [7].
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Objective assessment of the treatment effect after neo-
adjuvant treatment is only possible by histopathology in
the resected specimens. In patients with AEG and GC,
the presence of < 10% of vital residual tumor cells is
considered as a major pathologic response, and is associ-
ated with a significant survival benefit [8–10]. The diffi-
culty is to identify patients who do not respond or
progress under neoadjuvant treatment. Those patients
may not profit from neoadjuvant treatment, still suffer
from adverse events, and finally risk tumor progression.
In the setting of esophageal cancer, measurement of
early changes in tumor glucose uptake by use of 18-
fluorodeoxyglucose-PET (PET) and later PET-CT
yielded promising results for predicting response follow-
ing neoadjuvant chemotherapy [11]. Metabolic tumor
activity can be quantified by the standardized uptake
value (SUV), and it was shown that a drop of ≥35%
measured after 2 weeks of induction chemotherapy was
an accurate cut-off value to predict response [12]. This
cut-off at ≥35% was prospectively studied in the
MUNICON-I trial including 119 patients with AEG I
and II [13]. Metabolic response evaluation by PET-CT
accurately identified all non-responding tumors within
two weeks of treatment. In addition, there was a signifi-
cant survival difference between metabolic responders
and non-responders.
No data are currently available for early metabolic
response evaluation by PET-CT in patients with AEG III
and GC, and the potential benefit is therefore unclear.
We studied patients with AEG II/III and GC in a cohort
of patients using the criteria for early metabolic response
from the MUNICON-I trial to evaluate the accuracy and
feasibility of metabolic response evaluation by early
PET-CT following neoadjuvant CTX.
Methods
A retrospective cohort of 72 consecutive patients with
biopsy proven GC or AEG Siewert type II-III [14] was
included in this study. All patients underwent routine
staging, including, laboratory tests, upper GI-endoscopy
with endoscopic ultrasound (EUS) and 18FDG PET-CT
as reported previously [15]. Patients with stage cT2N+ or
cT3–4, Nx by EUS and PET-CT (UICC TNM Classifica-
tion, 7th edition, [16] underwent diagnostic laparoscopy
to exclude occult peritoneal carcinomatosis prior to
neoCTX. All patients were discussed in a multidisciplinary
specialized tumor board prior to treatment initiation. The
study was approved by the local ethics committee (PB
2016–00769).
Imaging by 18FDG positron emission tomography-CT
A baseline PET-CT was performed as part of the staging
procedure and an early response PET-CT, 14 days after
the first cycle of neoadjuvant CTX. Imaging was
performed on an in-line system (Discovery RX or
Discovery VCT; GE Healthcare). These systems integrate
a state-of-the art full ring PET scanner with a multi-slice
helical CT (LightSpeed 16 or VCT 64 slice; GE Health-
care) allowing for acquisition of co-registered CT and PET
images in one session. Patients fasted for at least 4 h be-
fore scanning, which started 50–60 min after the injection
of a standard dose of 340–370 MBq 18F-FDG. A low dose
CT (80 mA, 140 kV, 0.5-s tube rotation, 4.25-mm section
thickness, 867-mm scan length, and 22.5-s data acquisi-
tion time) was performed first. Immediately after CT, the
PET emission scan was acquired, with 2 min emission
time per cradle position (total PET-CT acquisition time
12–16 min). PET images were reconstructed using a
standard 3-dimensional iterative algorithm (ordered-sub-
set expectation maximization). Image reading was done
on screen using a commercially available software package
(Advantage workstation, version 4.4; GE Healthcare). For
quantitative measurement, a circular region of interest
was placed over the tumor in the slice with maximum
[18F]-FDG uptake in the baseline scan. A tumor was
defined as negative or non-avid when there was no meas-
urable activity over background [18F]-FDG uptake in the
tumor area defined by endoscopy and/or demonstrated as
mass in the integrated multi-slice CT. In the second PET
scan, the region of interest was placed according to the
baseline study using the surrounding anatomical land-
marks. Patients with a decrease of ≥35% SUV were classi-
fied as metabolic responders (12,13).
Neoadjuvant chemotherapy
Two neoadjuvant chemotherapy regimens were applied,
either 3 cycles ECF according the “MAGIC” regimen [5],
or 3 cycles of FLOT, consisting of biweekly oxaliplatin
85 mg/m2, day1; docetaxel 50 mg/m2, day2; and con-
tinuous infusion 5-FU 2600 mg/m2 days 1–2 [17, 18].
Adverse events were reported according to the National
Cancer Institute Criteria, version 3.0.
Surgery
Standardized resections were performed including sub-
total (80%) gastrectomy for distal GC, gastrectomy for
middle or proximal third GC and transhiatal extended
gastrectomy for AEG Siewert type II-III tumors [19].
Systematic D2-lymphadenectomy (LAD) was routinely
performed [20], and additionally LAD of the lower medi-
astinum for AEG types II/III. In few selected patients,
para-aortic lymph node dissection (D3-LAD, [20]) was
performed. Complications were recorded using the
Clavien-Dindo classification [21].
Pathology
Pathologic tumor regression was evaluated using a pub-
lished validated scoring system [8]. Patients with less
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than 10% residual tumor cells were classified as re-
sponders. All other patients were classified as non-
responders. All specimens were reviewed by an experi-
enced gastrointestinal pathologist (AW).
Follow-up
Patients were followed clinically and by contrast CT
(local tumor recurrence, lymph node metastases, sys-
temic metastases including peritoneal carcinomatosis) at
4-month intervals during the first year after surgery and
at 6-month intervals thereafter, and endoscopy at
6 months and yearly thereafter. Survival was calculated
from the day of study inclusion.
Statistical analysis
Differences in proportions were analyzed using Fisher’s
exact test. Inter-individual comparisons of quantitative
data were done by use of a Wilcoxon signed rank test.
Survival was estimated according to Kaplan-Meier.
Statistical comparisons between different groups of
patients were done with a log-rank test. All tests were
two-sided and done at the 5% level of significance with




From October 1, 2008 to October 31, 2013, 72 consecu-
tive patients with resectable, locally-advanced GC or AEG
II/III were included. Among them, 28 patients were finally
not eligible for neoadjuvant chemotherapy due to severe
comorbidities, patient’s decision, or peritoneal carcinoma-
tosis at diagnostic laparoscopy. In 44 patients planned for
neoCTX, 14 (32%) did not show FDG uptake and could
therefore not be further evaluated. The remaining 30
patients (68%) underwent neoCTX and were restaged by
PET-CT 14 days after beginning neoCTX. Patient charac-
teristics are shown in Table 1.
Chemotherapy
Nine patients (30%) received neoCTX with ECF [5], and
21 (70%) received FLOT [17, 18]. 8/9 patients pretreated
with ECF received the planned 3 cycles and one patient
refused the third cycle because of side effects. 20/21 (95%)
patients with FLOT received 3 full cycles and 1 patient
received 2 cycles due to severe bone marrow depression.
Surgery and perioperative complications
All but one patient proceeded to surgical resection
within 3 weeks, while it had to be postponed to week 5
due to bone marrow depression. Radical lymphadenec-
tomy was performed in all patients with a high median
number of resected lymph nodes of 43 (range 23–113).
Perioperative morbidity according to the Clavien-Dindo
classification was observed in 50% of patients, including
major complications grade IIIb in 4 (13%) and grade IV
in 1 (4%) patient. There was no in-hospital or 90-day
mortality. Surgical details are summarized in Table 2.
Pathology
Most patients had locally-advanced ypT3–4 tumors (83%),
and positive lymph nodes (67%). Advanced N-categories
ypN2–3 were detected in 50% of resected specimens.
Major pathologic regression occurred in 11/30 (36.7%) tu-
mors with only 2/30 (7%) showing a pathologic complete
Table 1 Patient characteristics
Parameter Median (range) n = 30 %













AEG Siewert Type II 12 40
AEG Siewert Type III 10 34


















Clinical TNM staging is based on EUS (uT) and/or CT or PET-CT (cN)
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remission. Major pathologic response in R0-resected pa-
tients was significantly associated with improved median
survival rates (not reached) compared to minor response
(28.2 months; 95% CI 16.7–39.7 months) by log-rank test
(p = 0.04). Results are summarized in Table 3.
Metabolic response
In 30 patients with PET positive primary tumors, median
SUV significantly decreased from 10.4 (range 4.0–29.8) to
5.0 (range 0–25.2) 14 days after the first cycle
neoCTX (p < 0.0001). Metabolic response was ob-
served in 20 (66.7%), and no response in 10 (33.3%)
patients. Prediction of pathologic response by meta-
bolic response on PET-CT resulted in a sensitivity of
90.9% (95%-CI: 57.1–99.5%), specificity 47.3% (95%-CI:
25.2–70.5%), positive predictive value (PPV) 50% (95%-CI:
27.8–72.1%), negative predictive value (NPV) 90% (95%-CI:
54.1–99.4%) and overall accuracy of 63.3% (95% CI:
38.5–78.6%). Although the overall accuracy is low, the
NPV is high with a correct identification in 9/10 true
non-responding tumors.
Metabolic response and prognosis
Median follow-up was 22.4 months (range 3.2–61.8) for
surviving patients. Median overall survival was signifi-
cantly better for metabolic responders than for non-
responders (median survival not reached and 28.
2 months, 95%-CI: 7.2–10.7 months, respectively, log-
rank p = 0.04). Survival curves are shown in Fig. 1.
Discussion
This cohort study in patients with locally advanced AEG
II/III and GC shows that metabolic response two weeks
after starting neoadjuvant therapy evaluation by FDG-
PET-CT, using the validated threshold for metabolic re-
sponders from the MUNICON-I intervention trial (13)
of ≥35% reduction of SUV does not accurately predict
overall pathologic response. It does however identify a
subgroup of patients that does not respond to neoCTX
with a specificity of 90%. In this cohort, this subgroup
compromised 14% (10/72) of the study population with
an inferior prognosis compared to PET responders.
Table 2 Surgical characteristics
Parameter n = 30 %
Type of resection
Subtotal gastrectomy 2 7
Gastrectomy 2 7
Extended gastrectomy 2 7




D2+ lower mediastinum 20 13
D3-paraaortic ± lower mediastinum 4 67






Grade I 3 10
Grade II 7 23
Grade IIIa 0 0
Grade IIIb 4 13
Grade IVa 1 4
Grade IVb 0 0
Grade V 0 0
aSplenectomy: n = 1
Table 3 Histopathology after neoadjuvant chemotherapy














ypN3 (AEG) 3 10
ypN3a (GC) 4 14
ypN3b (GC) 1 3
Tumor regression grading
Complete regression (Ia) 2 7
< 10% residual tumor (Ib) 9 30
≥ 10% and < 50% residual tumor (II) 6 20
≥ 50% residual tumor (III) 8 27
no regression (IV) 5 16
Modified tumor regression grading
Minor (grade II - IV, ≥ 10% residual tumor) 19 63
Major (grade Ia - Ib, < 10% residual tumor) 11 37
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The results of our study compare well to the results of
the MUNICON-1 trial in patients with esophageal can-
cer, where 110 patients with AEG I/II were evaluated by
PET-CT [13]. The authors claim that responders can be
identified by early metabolic imaging, however, 42% of
the 50 PET responders showed a minor regression like
the 50% observed in our study. The NPV for the meta-
bolic response was 100% in the MUNICON trial, which
is comparable to the 90% in our study and the 10%
difference is likely due to the low patient numbers and
different tumor entities. We therefore conclude that
metabolic response evaluation by PET-CT does not
accurately predict overall response but identifies non-
responders in both trials. We also confirmed that PET-
responders have a better prognosis than non-responders
(p = 0.04) with remarkably close survival rates (median
survival was not reached in PET-responders in both tri-
als and 26 months and 28.2 months respectively for PET
non-responders). In the MUNICON-I intervention trial,
chemotherapy was discontinued in metabolic non-
responders, thereby saving time, and reducing side-
effects and costs without compromising the outcome.
Less data is available for patients with gastric cancer.
Vallböhmer et al. [22] found no predictive value for the
FDG uptake in 40 gastric cancer patients. Ott and
colleagues [23] prospectively studied 49 GC patients
including Siewert type III tumors with a metabolic response
(SUV reduction ≥35%) by PET. Overall, 23/49 (47%)
patients had non-intestinal type cancers and 38/49 (78%)
were in the proximal third. Metabolic response correctly
predicted histopathologic regression in 11/16 responding
and 27/33 non-responding tumors. This resulted in a sensi-
tivity and specificity of 69 and 82%. PPV and NPV were 65
and 84% and overall accuracy was 78%. Median survival of
metabolic responders was not reached, and significantly
(p = 0.037) better than for non-responders (24.1 months).
Again, remarkably similar results were obtained in our
study. The lower NPV is likely attributable to the higher
proportion of non-intestinal tumors (46.9%) compared to
our study (20%) and the significantly lower baseline SUV
obtained in non-intestinal-type tumors.
In contrast to patients receiving chemotherapy alone,
early metabolic response evaluation by PET-CT was not
successful in patients receiving neoadjuvant chemoradia-
tion for esophageal and esophagogastric junction can-
cers. [24–26]. Technically, a higher cut-off value might
be better to predict histopathological response. Indeed, a
previous study from the Munich group [12] showed that
a 45% or more decrease in SUV would result in higher
specificity for histological response (86% versus 75%) but
most important, in a lower NPV. This was also true in
our study with a cut-off at 50% (data not shown). The
FDG uptake is not uniform among the subgroups.
Esophageal tumors, AEG I, show about 100% FDG
uptake, much higher than AEG III or GC, or diffuse type
cancer [15]. Therefore, the use of PET-CT is not
uniformly recommended, particularly in non-intestinal gas-
tric cancer including signet ring cell cancer [23, 27–29].
Distal gastric cancer with low differentiation grades,
including diffuse types are less likely to achieve major
tumor regression after chemotherapy [30]. A risk score
was evaluated in 410 patients receiving neoCTX for GC.
Well-differentiated tumor grading, intestinal tumor type
histology and tumor localization in the middle third of
the stomach were identified as the significant positive
predictive factors for histopathologic response and prog-
nosis. A prognostic index could be created based on
tumor localization, grading and type according to
Lauren classification that identified 3 risk groups (low,
intermediate and high) with significantly different
clinical and histopathological response rates and overall
survival times. [31]. Several molecular markers have
been investigated in view of characterizing tumor
entities and predicting tumor response and prognosis
following neoadjuvant treatment [32, 33], since a variety
of novel targeted therapeutic approaches are introduced
in cancer treatment [34]. In HER2-positive advanced GC
and AEG, the international phase III trastuzumab for
GC (ToGA) study showed a significant improvement in
the median overall survival of patients upon the addition
of trastuzumab to cisplatin and fluoropyrimidine back-
bone therapy [35]. In the MUNICON-II trial, salvage
Numbers at risk
PET responders 20 15 10 4 2 1
PET non-responders 10 8 4 2 1 0
Fig. 1 Overall survival according response PET-CT Overall survival
estimates of n = 30 patients according to Kaplan-Meier curves based
on their response PET-CT after two cycles of neoCTX. Numbers at
risk are shown in 12 month intervals
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neoadjuvant radiochemotherapy in metabolic non-
responders lead to local remissions in a considerable num-
ber of patients but was not able to change the clinical
course [36]. Altogether, metabolic non-responders may
profit from a therapeutic switch to these novel approaches.
Our study clearly has its limitations, mainly attributable
to the small study population which does not allow more
sophisticated statistical analysis including multivariate
testing, and all test results must therefore be interpreted
with caution. Despite these limitations, our results are re-
markably close to the results of two published comparable
studies, the MUNICON PET-CT trial in Siewert type I/II
tumors [13] and the PET-study in gastric cancer including
Siewert type III tumors [23] using early metabolic
response evaluation. Furher research could also include
assessing survival outcomes in patients classified as non-
responders by PET-CT with subsequent discontinuation
of neoadjuvant chemotherapy and comparing them with
those remaining on treatment.
Conclusions
In conclusion, our study in patients with AEG and GC
adds further evidence that response PET-CT reliably
detects metabolic non-responders and can therefore
identify patients who should either immediately proceed
to resection or receive a modified multimodality therapy.
PET-CT-guided neoadjuvant chemotherapy appears
feasible in patients with AEG and GC but important is-
sues remain to be addressed in future trials especially
standardization for metabolic imaging as planned by the
EORTC GI Group and NEOPEC Trial Group [37, 38].
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